PRODUCT TYPES – Page 17

Occupational exposure limit breach in oncology manufacturing: FDA/EMA investigation expectations

Identifying the signs of a potential OEL breach is the first step in the investigative process. Symptoms may manifest as:Click to read the full article.

Finished product blend uniformity failure during line clearance and changeover: how to build a deviation package that passes an inspection deep-dive

Identifying blend uniformity failure during line clearance hinges on observing specific symptoms or signals that indicate potential issues. These may include:Click to read the full article.

Cross-contamination risk during inspection prep: FDA/EMA investigation expectations

Identifying the symptoms or signals of potential cross-contamination is the first step in the investigation process. Employees and quality assurance professionals must remain vigilant for the following indicators:Click to read…

Finished product serialization data mismatch after process parameter adjustment: data integrity review steps for LIMS/EMR/ES and chromatography systems

Identifying symptoms of serialization data mismatch is the first step in addressing potential deviations. Common signals might include:Click to read the full article.

Occupational exposure limit breach in oncology manufacturing: risk assessment for patient safety

The initial step in responding to a potential OEL breach is to recognize the symptoms or signals that indicate an issue may exist. These signals can manifest in various forms:Click…

Finished product hardness / friability drift after packaging material change: manufacturing vs lab root cause mapping and required evidence

Identifying the symptoms of finished product hardness or friability drift is the first step in any investigation. Symptoms often manifest as:Click to read the full article.

Potency OOS in oncology manufacturing: risk assessment for patient safety

Recognizing the symptoms or signals indicative of a potency OOS event is fundamental in initiating an effective investigation. Common signs that warrant immediate attention include:Click to read the full article.

Finished product particulate matter OOS after method transfer to a new QC lab: stability strategy adjustments and packaging risk mitigation steps

The first step in addressing OOS results for particulate matter is recognizing the symptoms or signals that indicate a potential issue. These can manifest through:Click to read the full article.

Assay drift during shared facility campaign: FDA/EMA investigation expectations

Identifying symptoms of assay drift is the first step in effective investigation. Symptoms may manifest as deviations in test results, unexpected trends in data, or quality complaints from customers. Common…

Finished product assay OOS during PAI / FDA inspection readiness: updates to master batch record and in-process controls to prevent recurrence

When an OOS result is detected, earlier signals may have been evident yet overlooked. Awareness of these symptoms is key for proactive management:Click to read the full article.

Potency OOS during stability pull: FDA/EMA investigation expectations

Recognizing the symptoms of potential potency OOS deviations is the first step in your investigative process. Symptoms may manifest as:Click to read the full article.

Finished product CCIT failure after process parameter adjustment: CAPA plan that inspectors accept (with effectiveness checks and due dates)

Symptoms or signals that indicate a potential CCIT failure include:Click to read the full article.